Almon Einat Brill 4
4 · Protalix BioTherapeutics, Inc. · Filed Oct 6, 2010
Insider Transaction Report
Form 4
Almon Einat Brill
VP, Product Development
Transactions
- Sale
Common Stock
2010-10-04$9.02/sh−35,000$315,700→ 0 total(indirect: By Trust) - Exercise/Conversion
Stock Options (Right to Buy)
2010-10-06−70,000→ 116,848 totalExercise: $0.97Exp: 2016-08-13→ Common Stock (70,000 underlying) - Exercise/Conversion
Common Stock
2010-10-06$0.97/sh+70,000$68,040→ 0 total(indirect: By Trust) - Sale
Common Stock
2010-10-05$9.08/sh−20,000$181,600→ 0 total(indirect: By Trust) - Sale
Common Stock
2010-10-06$9.29/sh−15,000$139,350→ 0 total(indirect: By Trust)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The reporting person acquired 70,000 shares of common stock upon the exercise of outstanding options, all of which shares were sold by the reporting person.
- [F3]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- [F4]All these options are fully vested.
- [F5]Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, (ii) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020 and (iii) options to purchase 311,272 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018.